MUNICH — In patients with severe hypertriglyceridemia, plozasiran was well-tolerated, reduced triglycerides by up to 81% and prevented acute pancreatitis events compared with placebo, a speaker reported. "Severe hypertriglyceridemia is probably one of the largest gaps in the management of lipid disorders.
MUNICH — In patients with severe hypertriglyceridemia, plozasiran was well-tolerated, reduced triglycerides by up to 81% and prevented acute pancreatitis events compared with placebo, a speaker reported.
"Severe hypertriglyceridemia is probably one of the largest gaps in the management of lipid disorders.
Above 5 mmol/L is a gateway for all sorts of conditions that preventative cardiologists [and] diabetologists have difficulty accessing and treating because the treatments are not very effective," Gerald F.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
MUNICH — In patients with severe hypertriglyceridemia, plozasiran was well-tolerated, reduced triglycerides by up to 81% and prevented acute pancreatitis events compared with placebo, a speaker reported. "Severe hypertriglyceridemia is probably one of the largest gaps in the management of lipid disorders. Above 5 mmol/L is a gateway for all sorts of conditions that preventative cardiologists [and] diabetologists have difficulty accessing and treating because the treatments are not very effective," Gerald F.
Open the app view to save this story, compare related coverage, and continue from the same source.